Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results

Sana Biotechnology (NASDAQ:SANA) posted its earnings results on Monday. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02, Zacks reports.

Sana Biotechnology Stock Down 17.7 %

Shares of SANA stock opened at $2.28 on Wednesday. The firm has a market cap of $509.05 million, a PE ratio of -1.63 and a beta of 1.63. Sana Biotechnology has a 12 month low of $1.52 and a 12 month high of $10.50. The stock has a 50 day moving average of $3.06 and a 200-day moving average of $3.20.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Citizens Jmp raised Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a report on Tuesday. TD Cowen raised Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Sana Biotechnology in a research note on Tuesday. Finally, Jefferies Financial Group began coverage on Sana Biotechnology in a research note on Friday, March 14th. They issued a “buy” rating and a $7.00 price target on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.80.

Insider Activity

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of the company’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total value of $1,888,018.88. Following the sale, the insider now directly owns 4,541,511 shares in the company, valued at $29,474,406.39. This represents a 6.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 31.10% of the stock is currently owned by company insiders.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.